You are here

NeisVac-C Single Prime Study in Infants

Last updated on May 9, 2018

FOR MORE INFORMATION
Study Location
NZOZ Vitamed
Bydgoszcz, , 85-021 Poland
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neisseria Meningitidis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
8-11 weeks
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject is an infant aged 8 to 11 weeks at the time of first vaccination

- Subject is clinically healthy as determined by the investigator's clinical judgment
through collection of medical history and physical examination

- Subject was born at full term of pregnancy (>= 37 weeks) with a birth weight >= 2 kg

- The parent(s) or legally authorized representative of the subject provides written
consent for participation

- The parent(s) or legally authorized representative of the subject has the ability to
understand and comply with the requirements of the protocol

- The parent(s) or legally authorized representative and the subject will be available
for the duration of the study

- The parent(s) or legally authorized representative of the subject agrees to keep a
subject diary

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subject has a history of severe allergic reactions or anaphylaxis, or has a known
sensitivity or allergy to any components of the vaccines

- Subject has had an acute or chronic infection requiring systemic therapy (antibiotic
or antiviral) or other prescribed treatment within the 2 weeks prior to the first
vaccination in this study

- Subject has a rash or dermatologic condition which may interfere with injection site
reaction rating

- Subject currently has, or has a history of, any significant cardiovascular,
respiratory, hepatic, renal, metabolic, autoimmune, rheumatic, hematological,
neurological, or neurodevelopmental disorder

- Subject has a disease, or is currently undergoing a form of treatment, or was
undergoing a form of treatment within 30 days prior to study entry, that could be
expected to influence immune response

- Subject has received any blood products or immunoglobulins within 60 days of study
entry

- Subject has received a live vaccine within 4 weeks or an inactivated or subunit
vaccine within 2 weeks of the scheduled first vaccination

- Subject has previously been vaccinated against meningococcal C disease

- Subject has a known or suspected immune dysfunction

- Subject has a functional or surgical asplenia (e.g. due to a pathologic
hemoglobinopathy, leukemia, lymphoma, etc.)

- Subject was administered an investigational drug within six weeks prior to study entry
or is concurrently participating in a clinical study that includes the administration
of an investigational product

- Subject or his/her parent(s) / legally authorized representative are in a dependent
relationship with the study investigator or with a study team member; dependent
relationships include close relatives (i.e. children, partner/spouse, siblings) as
well as employees of the investigator or site conducting the study

NCT01218451
Pfizer
Completed
NeisVac-C Single Prime Study in Infants

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Meningococcal Vaccine, rLP2086, Repevax, N Meningitidis Serogroup B, Meningitis
NCT01323270
All Genders
11+
Years
Multiple Sites
Neisseria Meningitidis (Bacterial Meningitis), Invasive Pneumococcal Disease (IPD)
NCT00617760
All Genders
1+
Years
Multiple Sites
Neisseria Meningitidis
NCT01218451
All Genders
0+
Years
Multiple Sites
NeisVac-C Single Prime Study in Infants
A Phase 3b, Randomized, Open Label, Feasibility Study of a Single Priming Dose of Meningococcal Group C Conjugate Vaccine (NeisVac-C) in Infants
The purpose of this study is to assess the feasibility of a single priming dose of NeisVac-C in infants (at either 4 or 6 months of age), as determined by immune response.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Neisseria Meningitidis
  • Biological: Meningococcal group C polysaccharide conjugate vaccine
    0.5 mL dose, subcutaneous administration in right anterolateral thigh
    Other Name: NeisVac-C
  • Biological: Pneumococcal 13-valent conjugate vaccine
    0.5 mL dose, subcutaneous administration in right anterolateral thigh
    Other Name: Prevenar 13
  • Biological: Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
    0.5 mL dose, subcutaneous administration in right anterolateral thigh
    Other Name: Infanrix hexa
  • Experimental: Group 1
    Single dose of NeisVac-C vaccine at 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
    Interventions:
    • Biological: Meningococcal group C polysaccharide conjugate vaccine
    • Biological: Pneumococcal 13-valent conjugate vaccine
    • Biological: Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
  • Experimental: Group 2
    Single dose of NeisVac-C vaccine at 6 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
    Interventions:
    • Biological: Meningococcal group C polysaccharide conjugate vaccine
    • Biological: Pneumococcal 13-valent conjugate vaccine
    • Biological: Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
  • Active Comparator: Group 3
    Two doses of NeisVac-C vaccine at 2 and 4 months of age - Concomitant vaccinations of Infanrix hexa (0.5 mL) and Prevenar 13 (0.5 mL) at 2, 4 and 6 months of age - Booster vaccination with NeisVac-C, Infanrix hexa and Prevenar between 12 and 13 months of age
    Interventions:
    • Biological: Meningococcal group C polysaccharide conjugate vaccine
    • Biological: Pneumococcal 13-valent conjugate vaccine
    • Biological: Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
956
June 2012
January 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subject is an infant aged 8 to 11 weeks at the time of first vaccination
  • Subject is clinically healthy as determined by the investigator's clinical judgment through collection of medical history and physical examination
  • Subject was born at full term of pregnancy (>= 37 weeks) with a birth weight >= 2 kg
  • The parent(s) or legally authorized representative of the subject provides written consent for participation
  • The parent(s) or legally authorized representative of the subject has the ability to understand and comply with the requirements of the protocol
  • The parent(s) or legally authorized representative and the subject will be available for the duration of the study
  • The parent(s) or legally authorized representative of the subject agrees to keep a subject diary

Exclusion Criteria:

  • Subject has a history of severe allergic reactions or anaphylaxis, or has a known sensitivity or allergy to any components of the vaccines
  • Subject has had an acute or chronic infection requiring systemic therapy (antibiotic or antiviral) or other prescribed treatment within the 2 weeks prior to the first vaccination in this study
  • Subject has a rash or dermatologic condition which may interfere with injection site reaction rating
  • Subject currently has, or has a history of, any significant cardiovascular, respiratory, hepatic, renal, metabolic, autoimmune, rheumatic, hematological, neurological, or neurodevelopmental disorder
  • Subject has a disease, or is currently undergoing a form of treatment, or was undergoing a form of treatment within 30 days prior to study entry, that could be expected to influence immune response
  • Subject has received any blood products or immunoglobulins within 60 days of study entry
  • Subject has received a live vaccine within 4 weeks or an inactivated or subunit vaccine within 2 weeks of the scheduled first vaccination
  • Subject has previously been vaccinated against meningococcal C disease
  • Subject has a known or suspected immune dysfunction
  • Subject has a functional or surgical asplenia (e.g. due to a pathologic hemoglobinopathy, leukemia, lymphoma, etc.)
  • Subject was administered an investigational drug within six weeks prior to study entry or is concurrently participating in a clinical study that includes the administration of an investigational product
  • Subject or his/her parent(s) / legally authorized representative are in a dependent relationship with the study investigator or with a study team member; dependent relationships include close relatives (i.e. children, partner/spouse, siblings) as well as employees of the investigator or site conducting the study
Sexes Eligible for Study: All
8 Weeks to 11 Weeks   (Child)
Yes
Contact information is only displayed when the study is recruiting subjects
Poland,   Spain
 
 
NCT01218451
670901
Yes
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Baxter BioScience Investigator, MD Baxter Healthcare Corporation
Pfizer
May 2015

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now